Description
Section 1: Introduction Chapter 1: Introduction: An overview of host-directed therapies for tuberculosis Daniel Frank, Robert Mahon Section 2: Targeting immunometabolism Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism Lorissa Smulan, Hardy Kornfeld, and Amit Singhal Chapter 3: The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells Natalie Bruiners, Valentina Guerrini, Maria Laura Gennaro Chapter 4: HIF-1a as a potential therapeutic target for tuberculosis treatment Qingkui Jiang, Maria Laura Gennaro, Lanbo Shi Chapter 5: Nuclear receptors in host-directed therapies against tuberculosis Eun-Kyeong Jo Section 3: Enhancing anti-mycobacterial mechanisms Chapter 6: Autophagy as a target for host-directed therapy against tuberculosis Surbhi Verma, Raman Deep Sharma and Dhiraj Kumar Chapter 7: Metformin: a leading HDT candidate for TB Amit Singhal and Hardy Kornfeld Chapter 8: Statins as host-directed therapy for tuberculosis Noton K. Dutta, Petros C. Karakousis Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms Rikesh K Dubey, Apoorva Narain Section 4: Targeting immune cells Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis Paula Ruibal, Tom H.M. Ottenhoff, Simone A. Joosten Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma Sadiya Parveen, John R. Murphy, and William R. Bishai Chapter 12: Targeting suppressor T cells Lanie Kleynhans, Gerhard Walzl Chapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis Tobias Dallenga, Ulrich E. Schaible Chapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis Katrin D. Mayer-Barber, Christopher M. Sassetti Chapter 15: Mucosal-associated invariant and V9Vd2 T cells Charles K. Vorkas, Michael S. Glickman Chapter 16: Airway epithelial cells Anglica M. Olmo-Fontnez, Jordi B. Torrelles Section 5: Preclinical models for assessing HDTs Chapter 17: In vitro models of human granuloma formation to analyze host-directed therapies Liku B. Tezera, Michaela T. Reichmann, Basim Al Shammari, Paul T. Elkington Chapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis Pere-Joan Cardona, Cristina Vilaplana Chapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis Selvakumar Subbian, Gilla Kaplan Section 6: Clinical trials of HDTs and special considerations for study endpoints Chapter 20: Clinical trials of TB-HDT candidates Robert S. Wallis Chapter 21: Outcomes for clinical trials of host-directed therapies for tuberculosis Akshay N. Gupte, Sara C. Auld, William N. Checkley, Gregory P. Bisson Chapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis Elisa H. Ignatius, Kelly E. Dooley
